ARA-290
Overview
ARA-290, also known as cibinetide, is an 11-amino-acid linear synthetic peptide derived from the helix B region of erythropoietin (EPO). It selectively activates the innate repair receptor (IRR; β-common receptor/CD131 heterodimer) without stimulating erythropoiesis. It is widely used in laboratory and preclinical research as a model compound to investigate tissue protection, resolution of inflammation, neuropathic pain modulation, neuroregeneration, and related IRR-mediated signaling pathways in various in vitro and animal model systems.
Research Applications (Observational Data from Published Studies) The following points summarize observations reported in scientific literature from preclinical (in vitro/animal) and human clinical trials and are provided solely for informational and research-planning purposes:
- Neuropathic Pain and Neuroprotection Research: In rodent models of diabetic neuropathy, sarcoidosis-associated small-fiber neuropathy, and chemotherapy-induced peripheral neuropathy, as well as Phase 2/3 human trials in type 2 diabetes patients with painful neuropathy, ARA-290 administration significantly reduced pain scores (measured by NRS and NTSS-6), improved corneal nerve fiber density, and enhanced sensory thresholds without altering hemoglobin levels.
- Anti-Inflammatory and Immune Modulation Studies: In cell culture systems, LPS-challenged animals, and human Phase 2 trials (rheumatoid arthritis, sarcoidosis), ARA-290 reduced pro-inflammatory cytokines (TNF-α, IL-6, IL-12), promoted M2 macrophage polarization, accelerated inflammation resolution, and improved clinical disease activity scores.
- Wound Healing and Tissue Repair Models: In rodent models of skin excisional wounds, corneal injury, and chronic ulceration, ARA-290 accelerated wound closure, increased re-epithelialization, enhanced angiogenesis, and improved collagen organization through IRR activation.
- Cardiovascular and Renal Protection Research: In myocardial ischemia-reperfusion and acute kidney injury rodent models, as well as early human safety studies, ARA-290 reduced infarct size, preserved cardiac function, attenuated renal fibrosis, and decreased markers of tubular injury and inflammation.
Important Legal Disclaimer For laboratory research use only. Not for human or veterinary use. Not for diagnostic, therapeutic, cosmetic, or food purposes. Not approved by the FDA or any regulatory agency. Researchers are responsible for compliance with all applicable laws and institutional guidelines.
Chemical Information
- Sequence: pyroGlu-Glu-Gln-Leu-Ala-Glu-Lys-Glu-Ala-Gln-Ala-Glu-Ala-NH₂ (11 aa, N-terminal pyroglutamate, C-terminal amidated)
- Common Name: Cibinetide, ARA-290, ARA 290
- Molecular Formula: C₅₁H₈₄N₁₆O₂₁
- Molecular Weight: 1257.32 g/mol
- CAS Number: 1204669-37-9
- PubChem CID: 91810661
Loading...